562. Memantine Augmentation of Targeted Cognitive Training in Antipsychotic-Medicated Patients With Schizophrenia: Preliminary Clinical and Functional Results

Disabling impairment in clinical, cognitive, and psychosocial functioning persists in antipsychotic-medicated schizophrenia patients (SZ). While some patients respond to 30-40h of Targeted Cognitive Training (TCT), significant non-response rates have prompted pharmacologic augmentation strategies for enhancing response. Here we provide preliminary evidence for the daily use of the noncompetitive NMDA receptor antagonist, memantine (MEM), to potentiate the clinical and functional response to TCT in antipsychotic-medicated SZ.